You are here
Arcato Investor Verification - Room506
Arcato Laboratories Investor Registration
Arcato is seeking to raise $1 million. The company will be issuing Series B Convertible Participating Preferred Stock (the “Series B Shares”), which is in turn convertible into shares of the Company’s common stock (“Common Stock”).
Arcato Laboratories, Inc.
Address: 201 W. Main Street, Suite 300, PMB 317, Durham NC 27701
Contact Person: Christopher S. Meldrum
E-mail Address: firstname.lastname@example.org
Company website: www.arcatolabs.com
Arcato Laboratories commenced operations in 2011, and is commercializing proprietary products to treat oral discomfort caused by orthodontic appliances (braces).
The development, manufacture, marketing, sale, promotion, and distribution of Arcato's products are subject to comprehensive government regulation by the U.S. Food and Drug Administration and similar international regulatory agencies.
Arcato is currently undergoing 510(k) regulatory review for OraWaxTM, Arcato’s first product.
Use of Funds
Proceeds will be use for:
· GMP demonstration batch stability studies
· 510(k) submission to FDA
· GMP manufacturing scale up and initial production
· Sales, marketing, general and administrative expenses
· Hiring full-time executives for sales and marketing
· Funding and implementing a business continuation plan in the event of a death or disability to key executives
The money raised will allow us to get OraWaxTM onto the market.
For More Information
If you're interested in more information about the Arcato Labs investment opportunity, including all due diligence documentation, please start the process by filling out the application below. You'll be asked to provide basic contact information and also validate your identity.
This investment is only available to Accredited Investors as defined by the SEC. With new SEC regulations, once you've had a chance to review all the information, we'll also need to verify your status as an accredited investor.
If you have any questions regarding this investment, please contact Arcato Labs at email@example.com. If you have questions about the EarlyIQ software or process, please contact EarlyIQ at firstname.lastname@example.org.
NOTICE: THE INFORMATION CONTAINED HEREIN IS NOT, AND SHOULD NOT BE CONSTRUED AS AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY SECURITIES, AND IS QUALIFIED IN ITS ENTIRETY BY THE COMPANY’S PRIVATE PLACEMENT OFFERING MEMORANDUM, WHICH MUST BE DELIVERED PRIOR TO SUBSCRIPTION FOR THE OFFERING. THE INVESTMENT DESCRIBED HEREIN (OR IN THE ATTACHMENTS HERETO) HAS NOT BEEN APPROVED OR DISAPPROVED BY THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION (THE “SEC”), ANY STATE SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THESE AUTHORITIES PASSED UPON OR ENDORSED THE MERITS OR THE ACCURACY OR ADEQUACY OF THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL AND IS A CRIMINAL OFFENSE.